NAD+ / Intravenous NAD

ID: nad_plus

Aliases: nicotinamide adenine dinucleotide, NAD, IV NAD+, NAD infusion, NAD therapy, NAD+, NAD (BUFFERED), buffered NAD+

Type: compound

Route/form: intravenous infusion in wellness/research contexts; not the same as oral NAD precursors

Status: wellness_or_research

Evidence level: early human

Best data tier: early human + human physiology

Support scope: human, review/regulatory

Source types: early_human, human_physiology, review

Linked sources: 3

Broad outcomes: Brain / mood / sleep, Longevity / mitochondrial / redox, Muscle growth / performance / recovery, Pain / addiction / acute care

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• cellular redox cofactor
• NAD-dependent enzymes
• sirtuins
• PARPs
• CD38/NAD consumption axis

Optimization domains

• NAD metabolism
• aging
• mitochondrial
• fatigue
• neuro
• addiction
• redox

Research basis

• NAD+ biology is central to redox metabolism, DNA repair signaling, sirtuins, PARPs, and CD38-related aging discussions.
• Small human IV studies show measurable metabolome changes and provide route/tolerability anchors for the wellness-clinic claim set.

Limits, risks, and missing evidence

• Direct IV NAD+ evidence is mostly pharmacokinetic, tolerability, or observational rather than clinical outcome proof.
• Oral precursors, IV NAD+, NADH, CD38 inhibitors, and NAMPT activators are not interchangeable interventions.

Risk flags

• limited human outcome data
• IV infusion
• route specific evidence
• human physiology not outcomes
• wellness clinic claims
• NAD pathway
• oncology theoretical
• medical supervision
• cost burden

Linked papers, labels, and reviews

1. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
   human_physiology / pubmed_nad_iv_metabolome_2019
   Small human IV NAD+ pharmacokinetic/metabolome pilot; supports route/metabolite handling, not clinical efficacy.
2. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
   early_human / pubmed_nad_iv_nr_retrospective_2026
   Recent real-world tolerability pilot of commercial IV NAD+ and IV NR; observational and not proof of anti-aging, addiction, or performance benefit.
3. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
   review / pubmed_nad_boosting_molecules_review_2018
   Broad NAD-boosting review covering NR, NMN, CD38, PARP, sirtuins, aging, metabolic disease, and translational caveats.